Top in ID: Moderna booster shot, Ebola vaccinations in DRC
Click Here to Manage Email Alerts
An FDA advisory committee voted 19-0 in favor of a booster dose of Moderna’s COVID-19 vaccine, to be given at half the regular dose at least 6 months after the primary two-dose series.
The committee recommended the booster shot for people aged 65 years or older, people aged 18 to 64 years at high risk for severe COVID-19, and people aged 18 to 64 years whose occupational or institutional setting puts them at an increased risk for serious complications. A recap of the committee meeting was the top story in infectious disease last week.
Other top stories focused on Ebola vaccinations in the Democratic Republic of the Congo and new data on the prevalence of long COVID.
Read these and more in infectious disease below:
FDA advisory committee unanimously recommends Moderna booster shot
An FDA advisory committee on Thursday unanimously recommended the authorization of a booster dose of Moderna’s COVID-19 messenger RNA vaccine for certain people, to be given at half the regular dose. Read more.
DRC begins Ebola vaccinations following boy’s death
The Democratic Republic of the Congo has begun vaccinating people against Ebola after the recent death of a boy from the virus, health officials said. Read more.
More than half of COVID-19 survivors experience symptoms 6 months after recovery
More than half of COVID-19 survivors experience symptoms consistent with long COVID up to 6 months after recovery, data from a systematic review published in JAMA Network Open showed. Read more.
FDA committee recommends second J&J shot at 2 months
An FDA advisory committee on Friday unanimously recommended that anyone who received the Johnson & Johnson COVID-19 vaccine should be able to receive a second dose at least 2 months after receiving their initial shot. Read more.
‘A global wake-up call’: In shadow of COVID-19, TB deaths rise for first time in 15 years
Disruptions caused by the COVID-19 pandemic have reversed years of global progress in the fight against tuberculosis, leading to an increase in deaths from tuberculosis for the first time in over a decade, according to WHO’s 2021 Global TB report. Read more.